Werner syndrome is characterized by the premature appearance of features associated with normal aging and cancer predisposition. This syndrome occurs frequently in Japan, affecting 1 in 20,000 to 1 in 40,000 people. The therapeutic methods for this disease are very limited and it is expected that iPS cells can be used for the development of innovative therapies…
Pancreatic cancer is one of the deadliest cancers, with an overall five-year survival rate of less than six percent. Its high fatality is attributed to failure to diagnose the disease before it spreads to other organs, as well as its resistance to current therapies. …
Their findings are published today in the journal, Nature Scientific Reports. …
John Roeske, PhD, and colleagues presented how they developed and evaluated the technology at the recent annual meeting of the American Society for Therapeutic Radiology and Oncology. Their approach uses dual-energy imaging combined with fluoroscopy to view tumors during radiation therapy. This technology does not require an X-ray that produces both high-and low-energy images. Existing hardware can be used to eliminate visuals of the ribs and other bones making it easier to see the tumor…
Pioneering research, by academics at the Universities of Bristol, Nottingham and the University of the West of England (UWE Bristol), shows that a specific compound can inhibit the activity of a molecule which is key to how tumours form new blood vessels. The vessels are essential for the cancer cells to survive and multiply. The findings, published in the journal Oncogene, show that targeting a molecule called SRPK1 could stop progression of prostate cancer…
Statins, such as simvastatin, are commonly prescribed to lower high cholesterol levels. Statins work by blocking an early step in cholesterol production…
“The importance of this molecule is that it’s a next-generation and highly potent inhibitor of a known melanoma pathway. It was highly effective against melanoma and the method of our study — using patient-derived tumor samples grown in mice — makes us especially optimistic that we should see similar results in the human disease,” says John Tentler, PhD, investigator at the CU Cancer Center, associate professor at CU School of Medicine and one of the paper’s lead authors…
Triple negative breast cancers (TNBCs) have a high mortality rate owing to aggressive proliferation and metastasis and a lack of effective therapeutic options. However, Professor Auguste’s team, discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) in human TNBC cell lines and tissues, and demonstrated that it is a potential molecular target and biomarker for TNBC therapy and diagnosis. “No therapies are available to treat triple negative breast cancer cells and because of that patients have a poor prognosis,” said Professor Auguste, the recipient of a 2014 Presidential Early Career Award for Scientists and Engineers. The Identification of ICAM-1 as a TNBC target and biomarker may lead to the development of a new strategy and platform for addressing a critical gap in TNBC patient care, she added. …
The investigational three-drug regimen, which produced hepatitis C cure rates of 97 percent, is an oral interferon-free therapy. Previously, the typical treatment for hepatitis C after a liver transplant was an interferon-based therapy, usually given for 48 weeks. It had a much lower response rate, had a risk of organ rejection and was poorly tolerated because of the immunosuppressants required to prevent rejection. The new oral regimen — ABT-450, ombitasvir and dasabuvir (with or without ribavirin) — produces significantly fewer side effects and is prescribed for 24 weeks…
For the majority of patients in the study, olaparib was at least their third different cancer therapy. Based on the new data, the authors say olaparib warrants further investigation in phase III trials…